Zentek Announces Annual General Meeting on Thursday October 5th, 2023, at the Delta Hotel in Guelph, Ontario

GUELPH, ON / ACCESSWIRE / September 21, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased to announce its 2023 Annual General and Special Meeting will be held on Thursday, October 5th at 4:00 pm at the Delta Hotel in Guelph, Ontario. Capacity may be limited, and attendees must register by email at [e-mail]. The meeting will be live streamed for those who cannot attend in person and can be accessed with the following link: 2023 Annual General and Special Meeting | Zentek Ltd. at the time of the AGM.

"We look forward to meeting our shareholders once again to discuss the Company's achievements in the last year, the direction of the Company going forward, answering shareholder questions and to vote on important matters that will allow the board and management team to best move the Company forward," said Francis Dubé, Chairman and Chief Operating Officer for Zentek.

The Management Information Circular has been mailed to shareholders of record on Friday August 25th. Shareholders will be asked to vote on the following items:

• to appoint BDO as the auditors of the Company for the ensuing year and to authorize the directors to fix their remuneration;
• to elect the directors of the Company for the ensuing year;
• to consider, and, if deemed advisable, to pass an ordinary resolution approving the adoption of the Company's omnibus long-term incentive plan;
• to transact such other business as may properly come before the meeting or any adjournments or postponements thereof.

The nature of the business to be transacted at the meeting is described in further detail in the management information circular of the Company under the section entitled Matters to be Acted Upon, which was sent to shareholders commencing on or around September 5, 2023.

The Company is pleased to announce John Snisarenko B.Sc. MBA is included in the circular as a proposed new director. John is a senior executive with 35 years of specialty pharmaceutical, biologics, medical device and commercialization experience spanning from start-up to large pharma/biotech. Zentek believes John will bring significant value to the Board of Directors as the company moves forward with the Aptamer platform, especially for the therapeutic market.